Skylark Bio to Present New Preclinical Data for its Pendrin Gene Therapy Program for Hearing Loss at ASGCT 2026
Skylark Bio, a biotechnology company developing targeted genetic medicines for hearing loss, today announced that it will present new preclinical data for SKY-PEN, its Pendrin gene therapy program in development for SLC26A4-related hearing loss, at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting.
